Serum Levels of Carboxyterminal Propeptide of Type I Procollagen in Cancer Patients with Osteoblastic and Osteolytic Bone Metastases
暂无分享,去创建一个
L. Dogliotti | C. Raucci | A. Berruti | A. Piovesan | G. Osella | A. Angeli | M. Torta
[1] B. Riggs,et al. Role of type I procollagen propeptide assays in metabolic bone diseases , 1992 .
[2] C. Christiansen,et al. The carboxy-terminal propeptide of type I procollagen in serum as a marker of bone formation: the effect of nandrolone decanoate and female sex hormones. , 1991, Metabolism: clinical and experimental.
[3] G. Mundy. Mechanisms of osteolytic bone destruction. , 1991, Bone.
[4] J. Risteli,et al. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. , 1990, Clinical chemistry.
[5] J. Simes,et al. Prostatic cancer with bone metastases: serum alkaline phosphatase (SAP) as a predictor of response and the significance of the SAP "flare". , 1990, British journal of urology.
[6] S. Epstein. Serum and urinary markers of bone remodeling: assessment of bone turnover. , 1988, Endocrine reviews.
[7] P. Woll,et al. Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). , 1988, British Journal of Cancer.
[8] K. Mann,et al. Concurrent assays of circulating bone Gla-protein and bone alkaline phosphatase: effects of sex, age, and metabolic bone disease. , 1988, The Journal of clinical endocrinology and metabolism.